Peginterferon lambda-1a: all 21 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Pegylated Interferon Lambda Treatment for COVID-19TerminatedNCT04343976Phase 2Results posted
- Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19CompletedNCT04331899Phase 2Results posted
- A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus InfectionCompletedNCT02765802Phase 2Results posted
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedNCT01866930Phase 3Results posted
- Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedNCT01598090Phase 3Results posted
- Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta HepatitisWithdrawnNCT05953545Phase 2
- Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDVActive, not recruitingNCT05070364Phase 3
- TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Status unknownNCT04967430Phase 3
- Interferon Lambda Therapy for COVID-19WithdrawnNCT04388709Phase 2
- Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19CompletedNCT04354259Phase 2
- The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C PatientsCompletedNCT02063607Phase 1
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01795911Phase 2
- Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCompletedNCT01754974Phase 3
- Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCompletedNCT01718158Phase 3
- Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3CompletedNCT01616524Phase 3
- Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CWithdrawnNCT01447394Phase 3
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01309932Phase 2
- Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCompletedNCT01204762Phase 2
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
- Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1